Molecular Diagnostics Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for molecular diagnostics dealmaking

Molecular diagnostics partnering is driven by advanced genomic and biomarker-based testing technologies, with deal structures reflecting the growing role of precision diagnostics in clinical decision-making and therapeutic development.

This report provides a comprehensive and structured analysis of 830+ molecular diagnostics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how molecular diagnostics deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by technology platform, testing application, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a precision-driven and clinically integrated landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within molecular diagnostics partnerships, particularly where regulatory requirements, clinical utility, and testing accuracy are key considerations.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark diagnostic and precision medicine transactions
Prepare for negotiations with well-defined market context
Evaluate technology partners and collaboration opportunities
Support internal strategy with robust, defensible data
What's included
830+ molecular diagnostics collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, technology, and application)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for molecular diagnostics dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how molecular diagnostics partnerships are structured, negotiated, and valued.

Product Code: CP2102mol

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

2.1. Introduction
2.2. Molecular diagnostics deals over the years
2.3. Most active molecular diagnostics dealmakers
2.4. Molecular diagnostics deals by deal type
2.5. Molecular diagnostics deals by therapy area
2.6. Molecular diagnostics deals by industry sector
2.7. Deal terms for molecular diagnostics deals
- 2.7.1 Molecular diagnostics deals headline values
- 2.7.2 Molecular diagnostics deal upfront payments
- 2.7.3 Molecular diagnostics deal milestone payments
- 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

3.1. Introduction
3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

4.1. Introduction
4.2. Most active molecular diagnostics dealmakers
4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

5.1. Introduction
5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

Deal directory
Deal directory - Molecular diagnostics deals by company A-Z
Deal directory - Molecular diagnostics deals by deal type
Deal directory - Molecular diagnostics deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Molecular diagnostics deals since 2016
Figure 2: Active molecular diagnostics dealmaking activity since 2016
Figure 3: Molecular diagnostics deals by deal type since 2016
Figure 4: Molecular diagnostics deals by therapy area since 2016
Figure 5: Molecular diagnostics deals by industry sector since 2016
Figure 6: Molecular diagnostics deals with a headline value
Figure 7: Molecular diagnostics deals with an upfront value
Figure 8: Molecular diagnostics deals with a milestone value
Figure 9: Molecular diagnostics deals with a royalty rate value
Figure 10: Top molecular diagnostics deals by value since 2016
Figure 11: Most active molecular diagnostics dealmakers since 2016
Figure 12: Molecular diagnostics deals by technology type since 2016